270 related articles for article (PubMed ID: 12164555)
1. Neoadjuvant chemotherapy for operable breast cancer.
Green M; Hortobagyi GN
Oncology (Williston Park); 2002 Jul; 16(7):871-84, 889; discussion 889-90, 892-4, 897-8. PubMed ID: 12164555
[TBL] [Abstract][Full Text] [Related]
2. Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial.
Loibl S; von Minckwitz G; Raab G; Blohmer JU; Dan Costa S; Gerber B; Eidtmann H; Petrich S; Hilfrich J; Jackisch C; du Bois A; Kaufmann M
Ann Surg Oncol; 2006 Nov; 13(11):1434-42. PubMed ID: 16983592
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial comparing neo-adjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer (T4b N0-2 M0).
Deo SV; Bhutani M; Shukla NK; Raina V; Rath GK; Purkayasth J
J Surg Oncol; 2003 Dec; 84(4):192-7. PubMed ID: 14756429
[TBL] [Abstract][Full Text] [Related]
4. Current and future role of neoadjuvant therapy for breast cancer.
Untch M; Konecny GE; Paepke S; von Minckwitz G
Breast; 2014 Oct; 23(5):526-37. PubMed ID: 25034931
[TBL] [Abstract][Full Text] [Related]
5. Breast-conserving surgery in the neoadjuvant setting.
Brenin DR; Morrow M
Semin Oncol; 1998 Apr; 25(2 Suppl 3):13-8. PubMed ID: 9566202
[TBL] [Abstract][Full Text] [Related]
6. [Neoadjuvant Chemotherapy in breast cancer].
Suzuki E; Toi M
Nihon Rinsho; 2006 Mar; 64(3):536-9. PubMed ID: 16529046
[TBL] [Abstract][Full Text] [Related]
7. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy in breast cancer.
Charfare H; Limongelli S; Purushotham AD
Br J Surg; 2005 Jan; 92(1):14-23. PubMed ID: 15635596
[TBL] [Abstract][Full Text] [Related]
9. Current and future roles of neoadjuvant chemotherapy in operable breast cancer.
Kim R; Osaki A; Toge T
Clin Breast Cancer; 2005 Aug; 6(3):223-32; discussion 233-4. PubMed ID: 16137432
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy for local advanced breast cancer with stage IIIB.
Kim R; Osaki A; Tanabe K; Toge T
Oncol Rep; 2004 Jun; 11(6):1265-72. PubMed ID: 15138565
[TBL] [Abstract][Full Text] [Related]
11. Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14.
Steger GG; Galid A; Gnant M; Mlineritsch B; Lang A; Tausch C; Rudas M; Greil R; Wenzel C; Singer CF; Haid A; Pöstlberger S; Samonigg H; Luschin-Ebengreuth G; Kwasny W; Klug E; Kubista E; Menzel C; Jakesz R;
J Clin Oncol; 2007 May; 25(15):2012-8. PubMed ID: 17513805
[TBL] [Abstract][Full Text] [Related]
12. Primary systemic therapy for operable breast cancer patients: the need for the new generation of trial design.
Alvarez RH; Hortobagyi GN
Breast Cancer Res Treat; 2010 Dec; 124(3):701-5. PubMed ID: 20953832
[No Abstract] [Full Text] [Related]
13. Oncologic safety of breast-conserving surgery compared to mastectomy in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer.
Cho JH; Park JM; Park HS; Park S; Kim SI; Park BW
J Surg Oncol; 2013 Dec; 108(8):531-6. PubMed ID: 24115142
[TBL] [Abstract][Full Text] [Related]
14. Future prospects of neoadjuvant chemotherapy in treatment of primary breast cancer.
Wang HC; Lo SS
Semin Surg Oncol; 1996; 12(1):59-66. PubMed ID: 8821411
[TBL] [Abstract][Full Text] [Related]
15. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.
Kaufmann M; Hortobagyi GN; Goldhirsch A; Scholl S; Makris A; Valagussa P; Blohmer JU; Eiermann W; Jackesz R; Jonat W; Lebeau A; Loibl S; Miller W; Seeber S; Semiglazov V; Smith R; Souchon R; Stearns V; Untch M; von Minckwitz G
J Clin Oncol; 2006 Apr; 24(12):1940-9. PubMed ID: 16622270
[TBL] [Abstract][Full Text] [Related]
16. Recurrence rates after DCE-MRI image guided planning for breast-conserving surgery following neoadjuvant chemotherapy for locally advanced breast cancer patients.
Garimella V; Qutob O; Fox JN; Long ED; Chaturvedi A; Turnbull LW; Drew PJ
Eur J Surg Oncol; 2007 Mar; 33(2):157-61. PubMed ID: 17085007
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of neoadjuvant docetaxel/ vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer.
Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
Clin Breast Cancer; 2006 Feb; 6(6):511-7. PubMed ID: 16595034
[TBL] [Abstract][Full Text] [Related]
19. A multidisciplinary approach to neoadjuvant therapy for primary operable breast cancer. Challenges and opportunities.
Connolly R; Stearns V
Oncology (Williston Park); 2010 Feb; 24(2):135-43. PubMed ID: 20361464
[TBL] [Abstract][Full Text] [Related]
20. Primary systemic therapy of breast cancer.
Sachelarie I; Grossbard ML; Chadha M; Feldman S; Ghesani M; Blum RH
Oncologist; 2006 Jun; 11(6):574-89. PubMed ID: 16794237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
